Timing of Aminophylline and Recovery in Pediatric Ambulatory Surgery

NCT ID: NCT07011134

Last Updated: 2025-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-15

Study Completion Date

2025-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Beyond its established use as a bronchodilator and therapy for apnea of prematurity, aminophylline has demonstrated utility in reversing the effects of anesthetics, enhancing recovery by accelerating respiratory and cognitive functions. Variations in dosage (1-6 mg/kg) have been explored, but questions persist regarding optimal timing and dosing for pediatric surgical populations to achieve maximal efficacy with minimal adverse effects.

This randomized controlled study aims to evaluate the effect of early versus late aminophylline administration on recovery profiles in pediatric patients undergoing ambulatory surgery under sevoflurane anesthesia.

Sixty children aged 4-12 years will be randomly allocated into three groups: Group (E) will receive aminophylline early intraoperatively, Group (L) will receive aminophylline late intraoperatively, and Group (C) will receive normal saline post-anesthetic discontinuation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

An online randomization program (http://www. Randomizer.org) will be used to generate a random list and each patient's code will be kept in an opaque sealed envelope. Patients will be randomly allocated with 1:1:1 allocation ratio into three equal groups in a parallel manner:

* Group E (n=20): patients will receive aminophylline at an early intraoperative time immediately after fixation of ETT and confirmation of bilateral adequate lung ventilation (EtSevo\< 1).
* Group L (n=20): patients will receive aminophylline at late intraoperative time immediately after discontinuation of sevoflurane (EtSevo \< 1).
* Group (C) (n=20): patients will receive normal saline immediately after discontinuation of sevoflurane (EtSevo \< 1). Patients and outcome assessors will be blinded to the group of the patients. An independant anesthetist who is not involved in the study will prepare the interventional medications.

Preoxygenation with 100% oxygen will be done for 3 min. An intravenous cannula will be inserted after inhalational induction of sevoflurane at 8%. Then, General anesthesia will be induced by propofol (2.0 mg/kg), fentanyl (1.0 mcg/kg) and atracurium (0.5 mg/kg) endotracheal intubation will be performed after full relaxation.

Anesthesia will be maintained with sevoflurane (2.0%-3.0%) to keep EtSevo 2.0 % in an O2/air mixture, and top up doses of atracurium every 30 min. Fresh gas flow will be set at 3 L/min all through the intraoperative period. Minute ventilation will be adjusted to maintain normocapnia (end tidal carbon dioxide; et CO2, between 32- and 34-mm Hg application of 5.0 mmHg of PEEP).

Two syringes will be prepared by an independent anesthesiologist for each patient. One syringe contains 5.0 mg/kg aminophylline while the other syringe contains a similar volume of normal saline. Then according to the allocated group, the independent anesthesiologist injected the syringe in an appropriate time and rate (over 10 min). All patients will receive Lactated Ringer's solution infused at a rate of 2.0-3.0 mL/kg/h and dexamethasone at 0.15 mg/Kg as antiemetic. Normothermia will be maintained by warming the IV fluids and using Bair Hugger warming system.

In case of tachycardia (20% increase in the heart rate from the baseline reading) or hypertension (20% increase in the mean arterial pressure from the baseline reading), the depth of anesthesia will be increased by increasing the concentration of sevoflurane and administration of IV fentanyl at 1μg/Kg. In case of hypotension (20% decrease in the mean arterial pressure from the baseline reading); if fluid boluses failed to restore blood pressure back to normal the concentration of the sevoflurane will be reduced, and ephedrine will be administered in 5.0 mg/kg increments.

In the post-anesthesia care unit (PACU), the patient will be assessed immediately after admission and every 5 min using the Pediatric Post-Anesthetic Discharge Scoring System (Ped-PADSS) until it reaches at least 9 points; then the patient will be ready to discharge home. All patients will be given 0.5 mg/Kg I.V. boluses of pethidine if pain score ( Wong-baker faces pain scale) \> 4. Ramsay sedation scale will be recorded to distinguish 3 levels of sedation, where 0 means no sedation, 2-3 means conscious sedation, and 4-6 means deep sedation. Emergence delirium (ED) will be suspected if the child had a non-purposeful movement, seemed disorientated or confused, failed to interact normally with parents or caregiver or pulling IV lines, wound dressings or monitors. The Watcha scale will be used to assess postoperative emergence delirium (ED) in the recovery room. Diagnosis of ED will be considered if the child had a score of \>2 on the Watcha score.

Measurement tools:

* Demographic data (age, sex, weight), ASA physical status (I or II), type and duration of surgery (from skin incision utill completion of last stitch) and duration of anaesthesia (from iv induction utill sevoflurane discontinuation).
* Heart rate (HR) and mean arterial blood pressure (MBP) will monitored continuously and recorded at the following intervals: T0= immediately before I.V. induction of GA, T1= immediately after fixation of ETT (corresponding to the start time of drug administration in group E), T3= 15 min after fixation of ETT, T4= immediately before sevoflurane discontinuation, T5= 5 min after discontinuation of sevoflurane (corresponding to the ending time of drug administration in groups L and C, T6= 5 min after extubation, T7= 10 min after transfer to PACU.
* Ramsay sedation scale will be recorded 5 min after extubation, on admission to the PACU, and when the Pediatric Post-Anesthetic Discharge Scoring System (Ped-PADSS) \>9.
* Watcha scale to diagnose ED will be assessed 5min after PACU admission. ED will be considered if the child had a score of \>2 after being suspected clinically and before giving the rescue analgesics.
* Pediatric Post-Anesthetic Discharge Scoring System (Ped-PADSS) will be assessed and recorded immediately after PACU admission and every 5 min until it reached at least 9 points. Recovery of consciousness (ROC) time: defined as the time interval in minutes from discontinuation of sevoflurane anesthetic to eye opening in response to verbal or tactile command (extubation criteria).
* Home readiness discharge time: which is the time in minutes taken to home discharge decision; started from admission to PACU utill Ped PADSS reached at least 9.
* Total recovery time: which is the time in minutes started from discontinuation of sevoflurane anesthesia utill Ped-PADSS reached at least 9. Outcomes

Primary outcome:

• Recovery of consciousness (ROC) time was defined as the time interval in minutes from discontinuation of anesthetics to eye opening in response to verbal command or tactile stimulation.

Secondary outcome:

* Home readiness discharge time: which is the time in minutes taken to home discharge decision; started from admission to PACU utill Ped PADSS reached at least 9.
* Total recovery time: which is the time in minutes started from discontinuation of sevoflurane anesthesia utill Ped-PADSS reached at least 9.
* Level of sedation as assessed by Ramsay sedation scale 5 min after extubation, on admission to the PACU, and when the Pediatric Post Anesthetic Discharge Scoring System (Ped-PADSS).
* Incidence of ED as assessed by Watcha scale 5 min after PACU admission. Adverse events after aminophylline administration (e.g., arrhythmia, hypotension or hypertension, tremors, seizures, vomiting, shivering, agitation, rhabdomyolysis).

Ethical consideration:

Informed consent will be obtained from all parents involved in the study. There were adequate provisions to maintain the privacy of participants and confidentiality of the data.

Sample size calculation:

The sample size calculation was performed using G.power 3.1.9.2 (Universitat Kiel, Germany). The sample size was calculated based on the following considerations: 0.05 α error and 95% power of the study to demonstrate a 10% decrease in ROC (the primary outcome) with group E than group L (mean 4.53 min and SD 3.33 min, the mean was 8.93 min and SD was 0.92 min in group C according to a previous study). Two cases were added to each group to overcome dropout. Therefore, 20 patients were allocated in each group. Statistical analysis Statistical analysis will be done by SPSS v27 (IBM©, Chicago, IL, USA). The Shapiro-Wilks test and histograms will be used to evaluate the normality of the distribution of data. Quantitative parametric data will be presented as mean and standard deviation (SD) and will be analyzed by ANOVA (F) test with post hoc test (Tukey). Quantitative non-parametric data will be presented as median and interquartile range (IQR) and will be analyzed by Kruskal-Wallis test with Mann Whitney-test to compare each group. Qualitative variables will be presented as frequency and percentage and will be analyzed utilizing the Chi-square test. A two tailed P value \< 0.05 will be considered statistically significant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Recovery Pediatric Anesthesia Ambulatory Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group E will receive aminophylline at an early intraoperative time immediately after fixation of E

Group E (n=20): patients will receive aminophylline (5 mg/Kg) at an early intraoperative time immediately after fixation of ETT and confirmation of bilateral adequate lung ventilation (EtSevo\< 1).

Group Type ACTIVE_COMPARATOR

Group (E): receive aminophylline early intraoperatively,

Intervention Type DRUG

Group E (n=20): patients received aminophylline at an early intraoperative time immediately after fixation of ETT and confirmation of bilateral adequate lung ventilation (EtSevo\< 1)

Group L will receive aminophylline at late intraoperative time immediately after disco

Group L (n=20): patients will receive aminophylline (5 mg/Kg) at late intraoperative time immediately after discontinuation of sevoflurane (EtSevo \< 1)

Group Type ACTIVE_COMPARATOR

Group (L) received aminophylline late intraoperatively

Intervention Type DRUG

Group L (n=20): patients received aminophylline at late intraoperative time immediately after discontinuation of sevoflurane (EtSevo \< 1).

Group (C) will receive normal saline immediately after discontinuation of sevoflurane

Group (C) (n=20): patients will receive normal saline immediately after discontinuation of sevoflurane (EtSevo \< 1).

Group Type PLACEBO_COMPARATOR

Group (C) will receive normal saline post-anesthetic discontinuation.

Intervention Type DRUG

Group (C) (n=20): patients received normal saline immediately after discontinuation of sevoflurane (EtSevo \< 1).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Group (E): receive aminophylline early intraoperatively,

Group E (n=20): patients received aminophylline at an early intraoperative time immediately after fixation of ETT and confirmation of bilateral adequate lung ventilation (EtSevo\< 1)

Intervention Type DRUG

Group (L) received aminophylline late intraoperatively

Group L (n=20): patients received aminophylline at late intraoperative time immediately after discontinuation of sevoflurane (EtSevo \< 1).

Intervention Type DRUG

Group (C) will receive normal saline post-anesthetic discontinuation.

Group (C) (n=20): patients received normal saline immediately after discontinuation of sevoflurane (EtSevo \< 1).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Early aminophylline group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 4 to 12 years.

* Both sexes.
* American society of Anesthesiologist (ASA) physical status I-II.
* Scheduled for pediatric ambulatory elective surgical procedures lasting ≤ three hours duration.

Exclusion Criteria

* Parents refusal to participate.

* Conditions and diseases interfering with ambulatory day case surgery e.g., significant respiratory diseases, morbid obesity, obstructive sleep apnea, sickle cell anemia, prematurity, D.M, and family history of malignant hyperthermia.
* Laparoscopic, endoscopic or abdominal surgeries.
* History of cardiac arrhythmia or palpitation.
* Patients with congenital heart, significant cardiovascular, respiratory diseases, renal impairment, hepatic dysfunction, hypo/hyperthyroidism or active peptic ulcer disease.
* Patients with neurological, psychiatric diseases, cognitive dysfunction, epilepsy or history of convulsions.
* Current treatment with xanthines or patient received aminophylline in the previous 24 hr. Hypersensitivity to aminophylline or other methylxanthines.
* Patients who need alteration in the sevoflurane concentration due to either hypo/hypertension were excluded from the study and replaced.
Minimum Eligible Age

4 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hany Mohammed El-Hadi Shoukat Mohammed

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hany Mohammed El-Hadi Shoukat Mohammed

Assistant Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Neven AbdElmalk Gouda, MD

Role: STUDY_CHAIR

kasr Alainy Medical School/Cairo University

Menna T'Allah A.Mahmoud Gebril, MSc

Role: PRINCIPAL_INVESTIGATOR

kasr Alainy Medical School/Cairo University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hany M.El-Hadi Mohammed, MD

Role: CONTACT

Mohammed M. Kamel Anwar, MD

Role: CONTACT

+201005238534

References

Explore related publications, articles, or registry entries linked to this study.

El Tahan MR. Effects of aminophylline on cognitive recovery after sevoflurane anesthesia. J Anesth. 2011 Oct;25(5):648-56. doi: 10.1007/s00540-011-1190-8. Epub 2011 Jul 14.

Reference Type BACKGROUND
PMID: 21755342 (View on PubMed)

Chen Yang, Tingting Wu, Linrui Tang, Xuebing Zhang. A prospective observational study comparing the pediatric post anesthesia discharge scoring system with clinical discharge criteria in pediatric day surgical patients in Western China. Research square 2012.

Reference Type BACKGROUND

Kasim SA, Bahr MH, Abdelkader M, Rashwan DAE. The effect of preoperative aminophylline on the recovery profile after major pelvic-abdominal surgeries: a randomized controlled double-blinded study. BMC Anesthesiol. 2021 Apr 19;21(1):122. doi: 10.1186/s12871-021-01340-7.

Reference Type BACKGROUND
PMID: 33874898 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MS-408-2024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.